FLT3
シグナル伝達経路
研究分野
- 阻害剤の選択性比較
- 溶解度
| カタログ番号 | 製品カタログ | 溶解度(25°C) | ||
|---|---|---|---|---|
| 水 | DMSO | アルコール | ||
| S2194 | R406 | <1 mg/mL | 100 mg/mL | 0 mg/mL |
| S1526 | Quizartinib (AC220) | <1 mg/mL | 33 mg/mL | <1 mg/mL |
| S1018 | Dovitinib (TKI-258, CHIR-258) | <1 mg/mL | 30 mg/mL | <1 mg/mL |
| S1244 | Amuvatinib (MP-470) | <1 mg/mL | 32 mg/mL | <1 mg/mL |
| S1043 | Tandutinib (MLN518) | <1 mg/mL | 5 mg/mL | 6 mg/mL |
| S2692 | TG101209 | <1 mg/mL | 102 mg/mL | <1 mg/mL |
| S2158 | KW-2449 | <1 mg/mL | 67 mg/mL | 67 mg/mL |
| S1181 | ENMD-2076 | 1 mg/mL | 105 mg/mL | <1 mg/mL |
| S2769 | Dovitinib (TKI-258) Dilactic Acid | 70 mg/mL | 90 mg/mL | <1 mg/mL |
| S8057 | Pacritinib (SB1518) | <1 mg/mL | 11 mg/mL | <1 mg/mL |
| S8023 | TCS 359 | <1 mg/mL | 15 mg/mL | <1 mg/mL |
| S2018 | ENMD-2076 L-(+)-Tartaric acid | <1 mg/mL | 100 mg/mL | <1 mg/mL |
| S7765 | Dovitinib (TKI258) Lactate | 66 mg/mL | 100 mg/mL | 1 mg/mL |
| S7576 | UNC-2025 | 100 mg/mL | 25 mg/mL | 8 mg/mL |
| S8442 | TAK-659 | 4 mg/mL | <1 mg/mL | <1 mg/mL |
| S8229 | Brigatinib (AP26113) | <1 mg/mL | 1 mg/mL | 43 mg/mL |
| S7545 | G-749 | <1 mg/mL | 24 mg/mL | <1 mg/mL |
| S7754 | Gilteritinib (ASP2215) | <1 mg/mL | 100 mg/mL | 85 mg/mL |
| S7003 | AZD2932 | <1 mg/mL | 89 mg/mL | 5 mg/mL |
| S7533 | AMG 925 | <1 mg/mL | 0.01 mg/mL | <1 mg/mL |
- FLT3阻害剤(20)
| 製品コード | 製品説明 | 文献中Selleckの製品使用例 | お客様のフィードバック |
|---|---|---|---|
| S2194 |
R406R406 is a potent Syk inhibitor with IC50 of 41 nM in cell-free assays, strongly inhibits Syk but not Lyn, 5-fold less potent to Flt3. Phase 1. |
Platelets (3 x 108/mL) were preincubated with Y27632 (10 uM), R406 (1 uM), or a combination of Y27632 and R406 for 20 minutes followed by stimulation with oxLDL (50 ug/mL) for 15 seconds and lysis. Samples were then separated by SDS-PAGE and were immunoblotted for phospho-MLCSer19, followed by reprobing for β-tubulin. (Fi) Representative blots. (Fii) Densitometric analysis of 3 independent experiments. *P < .05. Data are presented as mean ± SEM. Experiments were carried out in the presence of apyrase (2 U/mL), indomethacin (10 uM), and EGTA (1 mM).
|
|
| S1526 |
Quizartinib (AC220)Quizartinib (AC220) is a second-generation FLT3 inhibitor for Flt3(ITD/WT) with IC50 of 1.1 nM/4.2 nM in MV4-11 and RS4;11 cells, respectively, 10-fold more selective for Flt3 than KIT, PDGFRα, PDGFRβ, RET, and CSF-1R. Phase 3. |
B. MOLM-14 cells were treated with PBS (control) or FLT3 inhibitor (100 nM) for 16 h, and were then stained for LC3B-FITC and analysed by flow cytometry. Histograms represent the percentages of LC3B-FITC medium fluorescence intensity (MFI) of cells treated with FLT3 inhibitor, normalized to PBS-treated cells (n=3 ± SEM). The FLT3 inhibitor is quizartinib.
|
|
| S1018 |
Dovitinib (TKI-258, CHIR-258)Dovitinib (TKI258, CHIR258) is a multitargeted RTK inhibitor, mostly for class III (FLT3/c-Kit) with IC50 of 1 nM/2 nM, also potent to class IV (FGFR1/3) and class V (VEGFR1-4) RTKs with IC50 of 8-13 nM, less potent to InsR, EGFR, c-Met, EphA2, Tie2, IGF-1R and HER2 in cell-free assays. Phase 4. |
In vitro assays on CUX1-FGFR1-expressing Ba/F3 cells. a. IL-3 deprivation of Ba/F3 cells transduced with CUX1-FGFR1 resulted in transformation to growth factor independent growth. The mean growth ±SEM of three separate measurements over four consecutive days is presented. b. The dose-response curves of CUX1-FGFR1-transduced Ba/F3 cells, treated with TKI258 and PKC412 for 48 hours in the absence or presence of IL-3 (2 ng/ml) are presented. Points represent the average results of two experiments done in triplicate plotted with the curve-fitting GraphPad Prism 5 software; bars, SD. The calculated IC50 for each inhibitor is indicated. c. Western blot analyses of CUX1-FGFR1-transformed Ba/F3 cells after treatment with PKC412 and TKI258. Phosphorylation of CUX1-FGFR1 and its downstream effectors STAT5 and RPS6K decreased with increasing inhibitor concentrations. Expression of total CUX1-FGFR1, STAT5 and RPS6K remained unaffected. d. Effect of PKC412 and TKI258 on apoptosis of CUX1-FGFR1-expressing Ba/F3 cells after treatment for 48 hours. The percentage of apoptotic plus necrotic CUX1-FGFR1-transduced Ba/F3 cells is indicated. |
|
| S1244 |
Amuvatinib (MP-470)Amuvatinib (MP-470) is a potent and multi-targeted inhibitor of c-Kit, PDGFRα and Flt3 with IC50 of 10 nM, 40 nM and 81 nM, respectively. Phase 2. |
Effects of treatment for 48h with a vehicle or the indicated doses of MP-470 in parental or ER1 and ER2 cell lines in the absence and presence of erlotinib on the indicated biomarkers. Data represent 3 independent experiments.
|
|
| S1043 |
Tandutinib (MLN518)Tandutinib (MLN518, CT53518) is a potent FLT3 antagonist with IC50 of 0.22 μM, also inhibits PDGFR and c-Kit, 15 to 20-fold higher potency for FLT3 versus CSF-1R and >100-fold selectivity for the same target versus FGFR, EGFR and KDR. Phase 2. |
A representative experiment for tandutinib is shown. A: The control group after 0 h. B: The control group after 24 h. C: Treatment with 0.125 ug/ml tandutinib. D: Treatment with 0.25 ug/ml tandutinib. E: Treatment with 0.5 ug/ml tandutinib. F: + Treatment with 1 ug/ml tandutinib. G: Treatment with 2 ug/ml tandutinib. H: Treatment with 5 ug/ml tandutinib. I: Treatment with 10 ug/ml tandutinib. (B) + (C) *, P < 0.05, compared with the respective uninhibited cells. The bars represent the mean ?SD.
|
|
| S2692 |
TG101209TG101209 is a selective JAK2 inhibitor with IC50 of 6 nM, less potent to Flt3 and RET with IC50 of 25 nM and 17 nM in cell-free assays, ~30-fold selective for JAK2 than JAK3, sensitive to JAK2V617F and MPLW515L/K mutations. |
EGFR-ERCC1 effect on survival. QGP1 cells were transfected with Scrambled, ERCC1, EGFR, or EGFR-ERCC1 siRNA. Following 48 hours of siRNA transfection, Scrambled siRNA and ERCC1 siRNA-transfected cells were treated with 1 umol/L gefitinib or 125 nmol/L NU7026 (DNAPK inhibitor), or both, while EGFR siRNA and EGFR-ERCC1 siRNA-transfected cells were treated with 125 nmol/L of NU7026 1 hour prior 4 Gy IR treatment. Survival of these cells was then assessed 72 hours following IR treatment via MTT assay. The graphs show percentage of survival from 3 independent experiments as compared with untreated control. Bars show SD. Asterisks show statistical significance (*,P < 0.05; **, P < 0.01; ***, P < 0.001; NS, nonsignificant).
|
|
| S2158 |
KW-2449KW-2449 is a multiple-targeted inhibitor, mostly for Flt3 with IC50 of 6.6 nM, modestly potent to FGFR1, Bcr-Abl and Aurora A; little effect on PDGFRβ, IGF-1R, EGFR. Phase 1. |
Western blot analysis of p-histone and histone. 0-10μM KW2449 was added.
|
|
| S1181 |
ENMD-2076ENMD-2076 has selective activity against Aurora A and Flt3 with IC50 of 14 nM and 1.86 nM, 25-fold selective for Aurora A than over Aurora B and less potent to VEGFR2/KDR and VEGFR3, FGFR1 and FGFR2 and PDGFRα. Phase 2. |
Breast cancer cells line MDA-MB-231 were treated with the indicated concentrations of ENMD-2076.
|
|
| S2769 |
Dovitinib (TKI-258) Dilactic AcidDovitinib Dilactic acid (TKI258 Dilactic acid) is the Dilactic acid of Dovitinib, which is a multitargeted RTK inhibitor, mostly for class III (FLT3/c-Kit) with IC50 of 1 nM/2 nM, also potent to class IV (FGFR1/3) and class V (VEGFR1-4) RTKs with IC50 of 8-13 nM, less potent to InsR, EGFR, c-Met, EphA2, Tie2, IGFR1 and HER2. Phase 4. |
In vitro assays on CUX1-FGFR1-expressing Ba/F3 cells. a. IL-3 deprivation of Ba/F3 cells transduced with CUX1-FGFR1 resulted in transformation to growth factor independent growth. The mean growth ±SEM of three separate measurements over four consecutive days is presented. b. The dose-response curves of CUX1-FGFR1-transduced Ba/F3 cells, treated with TKI258 and PKC412 for 48 hours in the absence or presence of IL-3 (2 ng/ml) are presented. Points represent the average results of two experiments done in triplicate plotted with the curve-fitting GraphPad Prism 5 software; bars, SD. The calculated IC50 for each inhibitor is indicated. c. Western blot analyses of CUX1-FGFR1-transformed Ba/F3 cells after treatment with PKC412 and TKI258. Phosphorylation of CUX1-FGFR1 and its downstream effectors STAT5 and RPS6K decreased with increasing inhibitor concentrations. Expression of total CUX1-FGFR1, STAT5 and RPS6K remained unaffected. d. Effect of PKC412 and TKI258 on apoptosis of CUX1-FGFR1-expressing Ba/F3 cells after treatment for 48 hours. The percentage of apoptotic plus necrotic CUX1-FGFR1-transduced Ba/F3 cells is indicated.
|
|
| S8057 |
Pacritinib (SB1518)Pacritinib (SB1518) is a potent and selective inhibitor of Janus Kinase 2 (JAK2) and Fms-Like Tyrosine Kinase-3 (FLT3) with IC50s of 23 and 22 nM in cell-free assays, respectively. Phase 3. |
||
| S8023 |
TCS 359TCS 359 is a potent FLT3 inhibitor with IC50 of 42 nM. |
||
| S2018 |
ENMD-2076 L-(+)-Tartaric acidENMD-2076 L-(+)-Tartaric acid is the tartaric acid of ENMD-2076, selective activity against Aurora A and Flt3 with IC50 of 14 nM and 1.86 nM, 25-fold more selective for Aurora A than Aurora B and less potent to VEGFR2/KDR and VEGFR3, FGFR1 and FGFR2 and PDGFRα. Phase 2. |
Breast cancer cells line MDA-MB-231 were treated with the indicated concentrations of ENMD-2076.
|
|
| S7765 |
Dovitinib (TKI258) LactateDovitinib (TKI258) Lactate is the Lactate of Dovitinib, which is a multitargeted RTK inhibitor, mostly for class III (FLT3/c-Kit) with IC50 of 1 nM/2 nM, also potent to class IV (FGFR1/3) and class V (VEGFR1-4) RTKs with IC50 of 8-13 nM, less potent to InsR, EGFR, c-Met, EphA2, Tie2, IGFR1 and HER2. Phase 4. |
(c) Percent survival for the AGS cancer cell line is shown with FGFR2 inhibitors of varying specificity. (d) The KatoIII diffuse gastric cancer cell line was treated with FGFR2 inhibitors of varying specificity. The Y-axis depicts percent survival versus the X-axis with log concentrations. In all panels, error bars represent standard error of the mean. The difference in percent cell survival between KatoIII and AGS cells was statistically significant (P <0.05) at the three highest concentrations of all drugs, except Brivanib which was only significant at the highest concentration. |
|
| S7576 |
UNC-2025UNC2025 is a potent and orally bioavailable dual MER/FLT3 inhibitor with IC50 of 0.74 nM and 0.8 nM, respectively, about 20-fold selectivity over Axl and Tyro3. |
||
| S8442 |
TAK-659TAK-659 is a potent and selective inhibitor of spleen tyrosine kinase (SYK) with an IC50 value of 3.2 nM. It is selective against most other kinases, but potent toward both SYK and FLT3. |
||
| S8229 |
Brigatinib (AP26113)Brigatinib (AP26113) is a potent and selective ALK (IC50, 0.6 nM) and ROS1 (IC50, 0.9 nM) inhibitor. It also inhibits ROS1, FLT3, and mutant variants of FLT3 (D835Y) and EGFR with lower potentcy. |
Immunoblotting analysis of H3122 and H3122-CER cells showing that brigatinib did not inhibit EGFR phosphorylation (p-EGFR). Total EGFR (t-EGFR) is also shown. Actin was used as a loading control. The cells were treated with brigatinib for 2 hours.
|
|
| S7545 |
G-749G-749 is a novel and potent FLT3 inhibitor with IC50 of 0.4 nM, 0.6 nM and 1 nM for FLT3 (WT), FLT3 (D835Y), and Mer, respectively, showing lower potency against other tyrosine kinases. |
||
| S7754 |
Gilteritinib (ASP2215)Gilteritinib(ASP2215) is a small-molecule FLT3/AXL inhibitor with IC50 values of 0.29 nM and 0.73 nM for FLT3 and AXL, respectively. It inhibits FLT3 at an IC50 value that was approximately 800-fold more potent than the concentration required to inhibit c-KIT (230 nM). |
||
| S7003 |
AZD2932AZD2932 is a potent and mutil-targeted protein tyrosine kinase inhibitor with IC50 of 8 nM, 4 nM, 7 nM, and 9 nM for VEGFR-2, PDGFRβ, Flt-3, and c-Kit, respectively. |
||
| S7533 |
AMG 925AMG 925 is a potent and orally bioavailable dual FLT3/CDK4 inhibitor with IC50 of 1 nM and 3 nM, respectively. |
-Hesperadin-AT9283-VX-680-PLoS-One-20150728.gif)
-Ponatinib(AP24534)-Genome-Biol-20150728.gif)
